Cargando…
Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH
The ability of vaccine-induced T cells to inhibit viral replication may contribute to protect against human immunodeficiency virus (HIV) acquisition. Here, we tested ex vivo viral inhibitory activity of T cell responses induced by a multivalent HIV vaccine based on the replication-incompetent recomb...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617392/ https://www.ncbi.nlm.nih.gov/pubmed/37811993 http://dx.doi.org/10.1128/jvi.01126-23 |
_version_ | 1785129598082613248 |
---|---|
author | van Duijn, Janine Stieh, Daniel Fernandez, Natalia King, Deborah Gilmour, Jill Tolboom, Jeroen Callewaert, Katleen Willems, Wouter Pau, Maria G. De Rosa, Stephen C. McElrath, M. Juliana Barouch, Dan H. Hayes, Peter |
author_facet | van Duijn, Janine Stieh, Daniel Fernandez, Natalia King, Deborah Gilmour, Jill Tolboom, Jeroen Callewaert, Katleen Willems, Wouter Pau, Maria G. De Rosa, Stephen C. McElrath, M. Juliana Barouch, Dan H. Hayes, Peter |
author_sort | van Duijn, Janine |
collection | PubMed |
description | The ability of vaccine-induced T cells to inhibit viral replication may contribute to protect against human immunodeficiency virus (HIV) acquisition. Here, we tested ex vivo viral inhibitory activity of T cell responses induced by a multivalent HIV vaccine based on the replication-incompetent recombinant adenovirus serotype 26 vector with a mosaic immunogen strategy (Ad26.Mos.HIV), designed for broad immune coverage of diverse HIV-1 strains. Using clinical trial samples with a diverse range of T cell responses measured by IFN-γ ELISpot, anti-viral function of vaccine-induced CD8+ T cells was assessed by inhibition of HIV-1 replication in autologous CD4+ T cells to a panel of HIV-1 isolates. Ex vivo expanded CD8+ T cells were able to inhibit replication of HIV in autologous CD4+ T cells, with 94% of vaccinees inhibiting at least one out of eight HIV isolates, and a median of 5 isolates inhibited at peak immunogenicity. Correlations between viral inhibition and ICS as well as ELISpot responses were explored, demonstrating positive correlations. Broad ELISpot responsiveness to different regions of the Env, Gag, and Pol proteins was associated with breadth of viral inhibitory responses. Moreover, polyfunctionality of CD8+ T cells correlated well with viral inhibition. These findings indicate that functional immunological breadth as well as antigenic breadth is important to induce antiviral activity. This study advances the understanding of vaccine-induced T cell functionality and demonstrates for the first time that Ad26.Mos.HIV vaccination in combination with adjuvanted gp140 can induce broad viral inhibitory activity toward a panel of diverse HIV-1 clades. IMPORTANCE: The functionality of CD8+ T cells against human immunodeficiency virus-1 (HIV-1) antigens is indicative of HIV-progression in both animal models and people living with HIV. It is, therefore, of interest to assess CD8+ T cell responses in a prophylactic vaccination setting, as this may be an important component of the immune system that inhibits HIV-1 replication. T cell responses induced by the adenovirus serotype 26 (Ad26) mosaic vaccine regimen were assessed previously by IFN-γ ELISpot and flow cytometric assays, yet these assays only measure cytokine production but not the capacity of CD8+ T cells to inhibit replication of HIV-1. In this study, we demonstrate direct anti-viral function of the clinical Ad26 mosaic vaccine regimen through ex vivo inhibition of replication of diverse clades of HIV-1 isolates in the participant’s own CD4+ T cells. |
format | Online Article Text |
id | pubmed-10617392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-106173922023-11-01 Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH van Duijn, Janine Stieh, Daniel Fernandez, Natalia King, Deborah Gilmour, Jill Tolboom, Jeroen Callewaert, Katleen Willems, Wouter Pau, Maria G. De Rosa, Stephen C. McElrath, M. Juliana Barouch, Dan H. Hayes, Peter J Virol Vaccines and Antiviral Agents The ability of vaccine-induced T cells to inhibit viral replication may contribute to protect against human immunodeficiency virus (HIV) acquisition. Here, we tested ex vivo viral inhibitory activity of T cell responses induced by a multivalent HIV vaccine based on the replication-incompetent recombinant adenovirus serotype 26 vector with a mosaic immunogen strategy (Ad26.Mos.HIV), designed for broad immune coverage of diverse HIV-1 strains. Using clinical trial samples with a diverse range of T cell responses measured by IFN-γ ELISpot, anti-viral function of vaccine-induced CD8+ T cells was assessed by inhibition of HIV-1 replication in autologous CD4+ T cells to a panel of HIV-1 isolates. Ex vivo expanded CD8+ T cells were able to inhibit replication of HIV in autologous CD4+ T cells, with 94% of vaccinees inhibiting at least one out of eight HIV isolates, and a median of 5 isolates inhibited at peak immunogenicity. Correlations between viral inhibition and ICS as well as ELISpot responses were explored, demonstrating positive correlations. Broad ELISpot responsiveness to different regions of the Env, Gag, and Pol proteins was associated with breadth of viral inhibitory responses. Moreover, polyfunctionality of CD8+ T cells correlated well with viral inhibition. These findings indicate that functional immunological breadth as well as antigenic breadth is important to induce antiviral activity. This study advances the understanding of vaccine-induced T cell functionality and demonstrates for the first time that Ad26.Mos.HIV vaccination in combination with adjuvanted gp140 can induce broad viral inhibitory activity toward a panel of diverse HIV-1 clades. IMPORTANCE: The functionality of CD8+ T cells against human immunodeficiency virus-1 (HIV-1) antigens is indicative of HIV-progression in both animal models and people living with HIV. It is, therefore, of interest to assess CD8+ T cell responses in a prophylactic vaccination setting, as this may be an important component of the immune system that inhibits HIV-1 replication. T cell responses induced by the adenovirus serotype 26 (Ad26) mosaic vaccine regimen were assessed previously by IFN-γ ELISpot and flow cytometric assays, yet these assays only measure cytokine production but not the capacity of CD8+ T cells to inhibit replication of HIV-1. In this study, we demonstrate direct anti-viral function of the clinical Ad26 mosaic vaccine regimen through ex vivo inhibition of replication of diverse clades of HIV-1 isolates in the participant’s own CD4+ T cells. American Society for Microbiology 2023-10-09 /pmc/articles/PMC10617392/ /pubmed/37811993 http://dx.doi.org/10.1128/jvi.01126-23 Text en Copyright © 2023 van Duijn et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Vaccines and Antiviral Agents van Duijn, Janine Stieh, Daniel Fernandez, Natalia King, Deborah Gilmour, Jill Tolboom, Jeroen Callewaert, Katleen Willems, Wouter Pau, Maria G. De Rosa, Stephen C. McElrath, M. Juliana Barouch, Dan H. Hayes, Peter Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH |
title | Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH |
title_full | Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH |
title_fullStr | Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH |
title_full_unstemmed | Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH |
title_short | Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH |
title_sort | mosaic hiv-1 vaccination induces anti-viral cd8(+) t cell functionality in the phase 1/2a clinical trial approach |
topic | Vaccines and Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617392/ https://www.ncbi.nlm.nih.gov/pubmed/37811993 http://dx.doi.org/10.1128/jvi.01126-23 |
work_keys_str_mv | AT vanduijnjanine mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT stiehdaniel mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT fernandeznatalia mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT kingdeborah mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT gilmourjill mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT tolboomjeroen mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT callewaertkatleen mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT willemswouter mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT paumariag mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT derosastephenc mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT mcelrathmjuliana mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT barouchdanh mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach AT hayespeter mosaichiv1vaccinationinducesantiviralcd8tcellfunctionalityinthephase12aclinicaltrialapproach |